Candida auris is an emerging fungus that presents a serious global health threat.
August 23rd, 2017August 21, 2017: Case Count Updated as of July 31, 2017
What’s New?
- August 21, 2017: case count updated to 112
- July 14, 2017: Updated recommendations on identification(https://www.cdc.gov/fungal/diseases/candidiasis/recommendations.html), treatment(https://www.cdc.gov/fungal/diseases/candidiasis/c-auris-treatment.html), and infection control(https://www.cdc.gov/fungal/diseases/candidiasis/c-auris-infection-control.html)
- June 26, 2017: Fact Sheet on Candida auris(https://www.cdc.gov/fungal/diseases/candidiasis/c-auris-drug-resistant.html)
- May 18, 2017: MMWR Notes from the Field on ongoing transmission(https://www.cdc.gov/mmwr/volumes/66/wr/mm6619a7.htm?s_cid=mm6619a7_w%20)
Candida auris is an emerging fungus that presents a serious global health threat. Healthcare facilities in several countries have reported that C. auris has caused severe illness in hospitalized patients. Some strains of C. auris are resistant to all three major classes of antifungal drugs. This type of multidrug resistance has not been seen before in other species of Candida. Also of concern, C. auris can persist on surfaces in healthcare environments and spread between patients in healthcare facilities. CDC has developed identification(https://www.cdc.gov/fungal/diseases/candidiasis/recommendations.html), treatment(https://www.cdc.gov/fungal/diseases/candidiasis/c-auris-treatment.html), and infection control(https://www.cdc.gov/fungal/diseases/candidiasis/c-auris-infection-control.html) recommendations to help prevent the spread of C. auris.
CDC encourages all U.S. laboratory staff who identify C. auris to notify their state or local public health authorities and CDC at candidaauris@cdc.gov.
Candida auris cases in the United States
Location represents the state of C. auris specimen collection. The case counts displayed reflect clinical cases of C. auris (i.e., based on specimens collected in the normal course of care). They do not include patients who screened for presence of C. auris colonization. C. auris has been isolated from an additional 120 patients from healthcare facilities in 4 states where clinical cases were detected. This map will be updated monthly.
Resources
- General Information about Candida auris(https://www.cdc.gov/fungal/diseases/candidiasis/candida-auris-qanda.html)
- Recommendations for Identification(https://www.cdc.gov/fungal/diseases/candidiasis/recommendations.html), Treatment(https://www.cdc.gov/fungal/diseases/candidiasis/c-auris-treatment.html), and Infection control(https://www.cdc.gov/fungal/diseases/candidiasis/c-auris-infection-control.html) of Candida auris
- June 2016 Clinical Alert: Information for Healthcare Professionals about Candida auris(https://www.cdc.gov/fungal/diseases/candidiasis/candida-auris-alert.html)
- Laboratory Submission Information(https://www.cdc.gov/fungal/lab_submission.html)
Publications
CDC Publications:
- Tsay, S., et. al. Ongoing Transmission of Candida auris in Health Care Facilities — United States, June 2016–May 2017(https://www.cdc.gov/mmwr/volumes/66/wr/mm6619a7.htm). MMWR, 2017, May 18.
- Berkow, et al. In vitro activity of a novel glucan synthase inhibitor, SCY-078, against clinical isolates of Candida auris. Antimicrob Agents Chemother. 2017 May 8.
- Vallabhaneni, S., et. al. Investigation of the first seven reported U.S. cases of Candida auris, a globally-emerging invasive fungus — United States, May 2013–August 2016(https://www.cdc.gov/mmwr/volumes/65/wr/mm6544e1.htm?s_cid=mm6544e1_w) . MMWR, 2016, Nov 4.
- Lockhart, S., et al., Simultaneous emergence of multidrug resistant Candida auris on three continents confirmed by whole genome sequencing and epidemiological analyses. Clinical Infectious Dis, 2016, Oct 20.
Candida auris reported from other countries:
India
- Chowdhary, A., et al., New clonal strain of Candida auris, Delhi, India. Emerg Infect Dis, 2013. 19(10): p. 1670-3.
Israel
- Ben-Ami, R., et al., Multidrug-Resistant Candida haemulonii and C. auris, Tel Aviv, Israel. Emerg Infect Dis, 2017. 23(2): p.195-203.
- Ben-Ami, R., et al., Antibiotic exposure as a risk factor for fluconazole-resistant Candida bloodstream infection. Antimicrob Agents Chemother, 2012. 56(5): p. 2518-23.
Japan
- Satoh, K., et al., Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol Immunol, 2009. 53(1): p. 41-4.
Kuwait
- Emara, M., et al., Candida auris candidemia in Kuwait, 2014. Emerg Infect Dis, 2015. 21(6): p. 1091-2.
South Afria
- Magobo, R.E., et al., Candida auris-associated candidemia, South Africa. Emerg Infect Dis, 2014. 20(7): p. 1250-1.
South Korea
- Choi, et al. Otomastoiditis caused by Candida auris: Case report and literature review. Mycoses. 2017 Apr 5.
- Lee, W.G., et al., First three reported cases of nosocomial fungemia caused by Candida auris. J Clin Microbiol, 2011. 49(9): p. 3139-42.
Spain
- Gaitán, A.C.R., et al. Nosocomial fungemia by Candida auris: First four reported cases in continental Europe. Rev Iberoam Micol, 2017, Jan 25.
United Kingdom
- Borman, A.M., et al. Isolates of the emerging pathogen Candida auris present in the UK have several geographic origins. Med Mycol. 2017 Feb 16.
- Schelenz, S., et al. First hospital outbreak of the globally emerging Candida auris in a European hospital. Antimicrob Resist Infect Control. 2016 Oct 19; 5:35.
Venezuela
- Calvo, B., et al. First report of Candida auris in America: Clinical and microbiological aspects of 18 episodes of candidemia. J Infect, 2016. 73(4): p.369-74.
Recommendations from other countries
- European Centre for Disease Prevention and Control. Candida auris in healthcare settings – Europe – 19 December 2016. Stockholm: ECDC; 2016.
- Candida auris identified in England. Public Health England. 2016, July 1.
- Candida auris: laboratory investigation, management and infection prevention and control. Public Health England. 2016, June 27.
Laboratory aspects of Candida auris
- Larkin, E., et al. The emerging pathogen Candida auris: Growth phenotype, virulence factors, activity of antifungals, and effect of SCY-078, a novel glucan synthesis inhibitor, on growth morphology and biofilm formation. Antimicrob Agents Chemother. 2017 Apr 24;61(5).
- Mizusawa, M., et al. Can a multi-drug resistant Candida auris be reliably identified in clinical microbiology laboratories? J. Clin. Microbiol, 2016, Nov 23.
- Sherry, L., et al., Biofilm-Forming Capability of Highly Virulent, Multidrug-Resistant Candida auris. Emerg Infect Dis, 2017.23(2): p. 328-31.
Other publications
- Azar, M.M., et al. Donor-derived transmission of Candida auris during lung transplantation. Clin Infect Dis. 2017 May 17.
- Clancy, C.J., et al. Emergence of Candida auris: an international call-to-arms. Clinical Infectious Dis, 2016, Oct 20.